Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity. - Test2 - elhamkhani - TriplyDB

Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.

Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.

http://www.wikidata.org/entity/Q33604248

about

Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.

P2860

Q33823686-631E81C4-3202-4BD3-8C7F-73C40BC89DEC

P2860

Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity.

http://www.wikidata.org/entity/Q33604248

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@ast

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@en

type

label

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@ast

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@en

prefLabel

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@ast

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@en

P1433

Q33604248-B7CB8750-50CB-4871-A208-ECA2687C6C25

P1476

Q33604248-40093915-FC56-4926-9729-2F6D55790040

P2093

Q33604248-083B3E89-2044-4492-BFCA-0E500B5B2097

Q33604248-3A2F6BCD-5F8A-48EF-AE2A-F434A1813CFA

Q33604248-6BA9ACDE-1D55-4060-8C25-A17E6144AEF9

Q33604248-8A941644-A384-45FA-8F26-99F98BAE25A2

Q33604248-D26EBED6-91A2-49FC-A82D-F69BC9BDEAB4

Q33604248-E3D5B5D1-B7D5-4A4A-8C4F-D598F84730A9

Q33604248-ED81A389-A4BB-428D-A0A0-29D2FAC45FAF

Q33604248-EF30AC47-6EFA-4F07-864A-D06F34C5DE6A

Q33604248-F33CC5FB-D2C0-42BD-AD78-CB898BC64FE9

P2860

Q33604248-373DA353-0E9A-47C8-B944-5F673B6BD630

Q33604248-5D2BD93D-F850-450B-BAB3-8E133B705010

Q33604248-68C65985-CB27-410D-90F4-643BB54F9CAF

Q33604248-6ECC3160-D4D1-4166-BFEB-E6213689BAA0

Q33604248-6F386CEB-3FA6-4A57-846B-831D07ADA792

Q33604248-705C1896-EAF9-4A51-81A3-D6297C960B00

Q33604248-7E703EC0-D3E8-4CF8-8BED-1ED4AF64D7EE

Q33604248-836BC932-7747-48E7-B79C-87B3A6CC9E57

Q33604248-8D050DBE-AA9A-469E-B894-6EE0F4204143

Q33604248-930DFA18-AEB7-4DA5-A642-7FE2F554C145

P304

Q33604248-A3F51D36-9F5C-4457-A222-50FB480D4F9B

P31

Q33604248-A8E9D308-93BB-49C5-B6C4-94B710A4F1DE

P356

Q33604248-82F027F2-8EB6-43A8-8206-93A40197CA0D

P478

Q33604248-C7D0348B-37B3-4FDC-93D6-B96E80D4D0F6

P577

Q33604248-DDE45F41-8531-448E-BD4F-BC0F4DA95F4F

P5875

Q33604248-B7F98627-D7A9-4756-AD92-BDA0FCD7E094

P698

Q33604248-E8044117-7A97-4B4F-97C6-D25EEFC52CC2

P932

Q33604248-70920A4F-C908-49FB-87BD-00F892FEA937

P356

ECANCER.2014.428

P1433

Ecancermedicalscience

P1476

Polymorphisms of uridine glucu ...... oes not protect from toxicity.

@en

P2093

Anna Ntokou

http://www.w3.org/2001/XMLSchema#string

Iakovos Armenis

http://www.w3.org/2001/XMLSchema#string

Konstantinos Konstantopoulos

http://www.w3.org/2001/XMLSchema#string

Marianna Tziotou

http://www.w3.org/2001/XMLSchema#string

Marianna Varsou

http://www.w3.org/2001/XMLSchema#string

Nicolas Tsavaris

http://www.w3.org/2001/XMLSchema#string

Revekka Tzanetea

http://www.w3.org/2001/XMLSchema#string

Vassiliki Kalotychou

http://www.w3.org/2001/XMLSchema#string

Yannis Rombos

http://www.w3.org/2001/XMLSchema#string

P2860

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.

Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians.

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.

Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.

P304

428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3332/ECANCER.2014.428

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262383234

http://www.w3.org/2001/XMLSchema#string

P698

24834123

http://www.w3.org/2001/XMLSchema#string

P932

4019457

http://www.w3.org/2001/XMLSchema#string